Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
26 June, 2017 07:28 IST
Aurobindo Pharma gets USFDA nod for anti-cough tablets
Source: IRIS | 21 Mar, 2017, 09.14AM
Comments  |  Post Comment

Aurobindo Pharma announced that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture Guaifenesin and Dextromethorphan Hydrobromide extended-release tablets, 600/30 mg and 1200/60mg (OTC). Aurobindo's Guaifenesin and Dextromethorphan Hydrobromide extended-release tablets are the AB rated generic equivalent of Reckitt Benckiser's Mucinex DM tablets. The product will be launched in Q1FY18.

Guaifenesin and Dextromethorphan Hydrobromide extended-release tablets helps loosen mucus and phlegm, and thin out bronchial secretions, making coughs more productive. The approved product has an estimated market size of US$ 235 million for the twelve months ending December 2016 according to IRI database.

This is the 106 th ANDA (including 21 tentative approvals) approved out of Unit VII formulation facility in Hyderabad, India used for manufacturing oral products. Aurobindo now has a total of 311 ANDA approvals (272 Final approvals including 16 from Aurolife Pharma LLC and 39 tentative approvals) from USFDA.

Shares of the company gained Rs 1.7, or 0.24%, to trade at Rs 704.90. The total volume of shares traded was 0 at the BSE (9.01 a.m., Tuesday).



Aurobindo Pharma Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Piramal Enterprises gets nod to raise up to Rs 1.25 bn - 23-Jun-2017 16:00
Bajaj Finance raises Rs 6 bn through issue of NCDs - 23-Jun-2017 11:04
ABAN Offshore arm bags order from Brunei Shell Petro for 5 years - 23-Jun-2017 10:47
Wockhardt settles ongoing commercial litigation with Teva - 23-Jun-2017 10:34
EID Parry's division forges partnership with Synthite Ind - 23-Jun-2017 10:28
Shriram EPC secures multiple orders worth Rs 1.65 bn - 23-Jun-2017 09:41
Wipro collaborates with Red Hat for cloud application factory - 23-Jun-2017 09:20
Reliance Defence to partner with Daher for aerospace components - 23-Jun-2017 09:16
Strides Shasun, Vivimed Labs achieve closure to set up JV in India, Singapore - 22-Jun-2017 14:26
PI Industries enters into JV agreement with Kumiai Chemical - 22-Jun-2017 14:22
Lupin launches generic Topicort LP Emollient Cream, Topicort cream in US - 22-Jun-2017 14:17
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer